NCT01131689已完成1 期
Phase 1 Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- MTD
研究概览
简要总结
In preclinical studies, 5-fluorouracil, one of the active metabolites of S-1, showed synergistic effect to sorafenib in human colon carcinoma cell lines. Therefore, sorafenib combined with S-1 might be more effective treatment for patients with advanced HCC than sorafenib monotherapy. The investigators propose to conduct a phase I study to determine maximal tolerated dose (MTD) of S-1 in combination with fixed dose of sorafenib in patients with advanced HCC
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed hepatocellular carcinoma (HCC) or a combination of radiologically compatible finding to HCC, alpha-fetoprotein>400ng/mL and liver cirrhosis
- •Inoperable disease as defined by
- •Localized disease in a portion of the liver that doses not allow the possibility of complete surgical removal of the tumor with a clear resection margin OR
- •Presence of extra-hepatic disease OR
- •Main portal vein or hepatic vein involvement (invasion or tumor thrombus) OR
- •The HCC must not be amenable to intra-arterial therapy or local ablative therapy
- •Minimum life expectancy of 12 weeks
- •Age>18 years.
- •ECOG Performance Status of 0-1
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •Hemoglobin>9.0 g/dl
- •Absolute neutrophil count (ANC) >1,500/mm3
- •Platelet count > 75,000/μl
- •Total bilirubin < 1.5 times the upper limit of normal
- •ALT and AST <5 x upper limit of normal
- •Albumin >= 3g/dL
- •PT-INR/PTT <1.5 x upper limit of normal
- •Serum creatinine < 1.5 x upper limit of normal or Creatinine clearance >=50mL/min
- •Signed and dated informed consent before the start of specific protocol procedures.
排除标准
- •Decompensated cirrhosis or stage C according to the Child-Pugh Classification
- •Chemo-embolization within 8 weeks of inclusion
- •Other concomitant anticancer agent, including Tamoxifen and Interferon
- •History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.
- •History of HIV infection
- •Active clinically serious infections (> grade 2 CTCAE version 3.0)
- •Symptomatic metastatic brain or meningeal tumors
- •Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •History of organ allograft
- •Patients with evidence or history of bleeding diathesis
- •Patients undergoing renal dialysis
- •Radiotherapy during study or within 4 weeks of start of study drug.
- •Major surgery within 4 weeks of start of study
- •Autologous bone marrow transplant or stem cell rescue within 4 months of study
- •Prior exposure to the study drug.
- •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial (and men for at least 3 months after last administration of study medication).
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- •Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- •Patients unable to swallow oral medications.
结局指标
主要结局
MTD
时间窗: 1 year
Primary objectives: 1\. To determine maximal tolerated dose (MTD) of S-1 combined with fixed dose of sorafenib 400mg twice daily. Secondary objectives: 1\. To evaluate toxicity profiles and dose-limiting toxicity (DLT)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Phase I/II Study of SOL for Untreated Metastatic Colorectal CancerColorectal CancerNCT00524706Shizuoka Cancer Center42
已完成
1 期
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00134069National Cancer Institute (NCI)48
已完成
1 期
A phase 1 study of 5-FU and sorafenib combination therapy in patients with hepatocellular carcinoma. Non-blind dosage gradual increase studyHepatocellular carcinomaJPRN-UMIN000004313Hokkaido University Hospital
终止
1 期
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Blastic Phase Chronic Myelogenous LeukemiaRecurrent Adult Acute Myeloid LeukemiaUnspecified Adult Solid Tumor, Protocol SpecificNCT01159301National Cancer Institute (NCI)44
已完成
1 期
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic MalignanciesInfantile Leukemia (Both AML and ALL)Acute Myeloid LeukemiaMyelodysplastic/Myeloproliferative NeoplasmsBiphenotypic LeukemiaMyelodysplastic SyndromeNCT00908167St. Jude Children's Research Hospital44